PART I: ANTI-VEGF THERAPY FOR AMD.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): Heier, Jeffrey S.
  • Source:
    Ophthalmology Times. 6/1/2006 Supplemment 2, Vol. 31, p4-6. 3p.
  • Additional Information
    • Subject Terms:
      RETINAL degeneration; THERAPEUTICS; VASCULAR endothelial growth factors; NEOVASCULARIZATION; PATHOLOGICAL physiology; VISION disorders
    • Abstract:
      The article focuses on the anti-vascular endothelial growth factor (VEGF) treatment for the age-related macular degeneration (AMD). In industrialized nations, AMD is considered to be a leading cause of irreversible vision loss for individuals age 50 years and older. VEGF is a powerful stimulator of angiogenesis and plays an important role in the pathophysiology of exudative AMD. The treatment of VEGF in the neovascularization of AMD is a new concept. There are various anti-VEGF treatments are available or in clinical development. Pegaptanib sodium is one of them which has been approved for the treatment of all AMD subtypes. It is considered to be the first by which VEGF is specifically targeted.